The capital infusion positions GramEye to scale its diagnostic platform, potentially reshaping clinical workflows and capturing market share in a rapidly digitizing healthcare sector.
Osaka‑based GramEye announced a Series B round of ¥570 million, led by Beyond Next Ventures with participation from existing backers Samurai Incubate and NES Inc. The AI‑driven diagnostic device maker will use the capital to accelerate product development and market expansion.
Comments
Want to join the conversation?
Loading comments...